• Formulate search strategies by aligning clinical trial inclusion/exclusion criteria with codified ontologies, identifying potential trial-ready patients from national claims and provider-based data sets.• Analyze clinical trial feasibility by developing opportunity assessment rubrics; incorporating disease prevalence, study drug costs, and data solution alignment.• Verify patient eligibility and generated chase lists to convert targets into enrollment candidates. Partner with clinical experts to refine discovery processes and advised clients on enhancing patient recruitment strategies.

• Developed clinical and lab testing workflows to inform a solid tumor molecular testing strategy; implemented performance standards and operational metrics to enforce process for a pilot program between two notable academic centers. • Investigated new sequencing technologies and oncologic assays to refine an optimal testing strategy designed to address the most prevalent solid tumor indications (i.e., NSCLC, Colorectal, Breast, Prostate). • Created external facing presentations and position papers (for investors and prospective customers) regarding lab strategy, sequencing technology application, and clinical workflow implementation.

• Identified high priority devices to initiate an infusion management product portfolio (i.e., IV bags, IV sets, supplemental monitors, needleless connectors, catheters, etc.) at a medical device start-up. • Conducted primary market surveillance and analyzed insight reports to draft product requirements for development / manufacturing.• Drafted business plan, financial model, pricing tiers, and market strategy to support portfolio launch readiness.

• Translated requirements, developed concepts, and delegated tasks across cross-functional departments (e.g., copy, medical, art, etc.) to facilitate the production of pharmaceutical marketing materials and education pieces for healthcare providers.• Owned the budget, resource planning, and invoice reconciliation for client projects. Additionally, lead status calls, prioritize work items in project plans, and manage expectations with clients regarding scope and deliverables.

• Maintained detailed functional work plans and collaborated with project leads to identify issues and navigate resolutions to support ongoing integration activities following the June 2016 acquisition of Baxalta Corp.• Developed milestone review templates and financial synergy reports for reoccurring Steering Committee and Integration Management team meetings with key stakeholders and senior executive leadership.

• Captured cross-functional R&D (clinical & labs) business needs for a contract management system; further created a consolidated system of vendor data to compare services and assess future contract award decisions.• Supported a new Vendor Strategy and Management group by developing frameworks, creating process flows, and drafting SOPs with corresponding training materials and job aids.

• Created and executed project work plans, developed meeting materials, and drafted supporting documentation (e.g., business plans, financial P&Ls, RFPs, etc.) to facilitate operations at a leading cancer institution’s research laboratories. • Collaborated with principal investigators and departmental financial managers to create annual clinical research budgets, and prepare monthly financial reports for institution-wide, high-value initiatives.• Conducted market research on industry trends to aid in project planning and critical decision-making.

• Prepared large-scale organizations for end-user adoption of ERP systems (e.g., Workday): enterprise services specializing in Human Capital Management, Payroll and Financial Management. • Served as a client-side leader in organizational behavior; a liaison identifying departmental change readiness and resistance barriers, and as a change ambassador developing communications and training seminars.

• Gathered functional requirements from stakeholders for a business intelligence solution at the NYS Energy Research Development Authority and provided deployment scenarios (cost, process improvements, user adoption) for a SQL, PowerPivot, and SharePoint analytics platform. • Served as Process Owner at the NYS Office of Mental Health for Agile Methodology Training. Produced a “how-to” tutorial on the functionality of Microsoft’s Team Foundation Server 2010 to support VistA EMR programming.

• Evaluated over 200 quality assessment reports for data that led to the identification of a 30% increase in drug trial process improvements over a 3-year span for clinical site noncompliance activities. • Revised Standard Operating Procedures (SOPs) and training methodologies that would improve 4 non-compliant international clinics to standard and allow for continuation in critical drug studies.

• Served on the Incentive Zoning/ Transfer of Development Rights Committee for the accommodation of the Clifton Park Global Foundries microprocessor plant; scheduled for construction in 2012 as part of a $665 million state subsidized initiative. • Developed a Saratoga Country Housing Report that considered the availability of existing residential infrastructure and mandated tax levies for an additional 3000-person work force.

• Oversaw cross-functional teams of research technicians and medical professionals to develop a proprietary analytical method that quantifies innervation patterns in skin biopsies to determine drug efficacy. • Designed the methodology for industry sponsored clinical research that aligned novel therapeutic safety objectives with the ChemoMorphic Analysis performed in the lab.

• Identified go-to-market strategies and regulatory pathways that would potentially save 2-3 years on getting therapeutics to the U.S. market via the FDA Orphan Drug Act. • Research market potential on the $4.9 billion dollar global osteoarthritic pain market for Korean Therapeutic; Apitoxin, and evaluated competitor financial statements using Capital IQ and created a 5-year valuation model for the client.

• Analyzed biotechnology industry reports across a range of secondary sources to determine investment potential for a portfolio of key drug candidates.• Constructed internal shareholdings portfolio including approximately 30 large, publicly traded pharmaceutical companies, and developed a net asset value method to validate the Group’s invested securities.